Last reviewed · How we verify
NCT05210868
A Phase I/II Study of CM355 in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL)
Phase 1, PHASE2 trial testing CM355 in Hematoma in 184 participants. Participants enrolled and being followed up; not accepting new ones.
28 December 2026
Quick facts
| Lead sponsor | Beijing InnoCare Pharma Tech Co., Ltd. |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 184 |
| Start date | 16 November 2021 |
| Primary completion | 28 December 2026 |
| Estimated completion | 31 December 2026 |
| Sites | 1 location across China |
Drugs / interventions tested
- CM355 — full drug profile →
Conditions studied
- Hematoma — all drugs for Hematoma →
Sponsor
Beijing InnoCare Pharma Tech Co., Ltd. — full company profile →
Who can join
18 and older, any sex, with Hematoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A Phase I/II Open-Label, Single-Arm, Multicenter Clinical Study of CM355 in Patients With R/R B-NHL
Publications & conference data
4 peer-reviewed publications reference this trial (live from Europe PMC):
-
Bi- and trispecific immune cell engagers for immunotherapy of hematological malignancies.
Tapia-Galisteo A, Álvarez-Vallina L, Sanz L. · · 2023 · cited 87× · PMID 37501154 · DOI 10.1186/s13045-023-01482-w -
Bispecific Antibodies for Lymphoid Malignancy Treatment.
Bisio M, Legato L, Fasano F, Benevolo Savelli C, et al · · 2024 · cited 4× · PMID 39796723 · DOI 10.3390/cancers17010094 -
EHA2024 Hybrid Congress
· 2024 -
Trial watch: bispecific antibodies for the treatment of relapsed or refractory large B-cell lymphoma
Cassanello G, Luna de Abia A, Falchi L. · · 2024
Verify or expand the search:
- PubMed search for NCT05210868
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Hematoma
Currently open trials in the same condition.
- NCT06791577 — Bridging the Healing Gap: A Single-Blind Clinical Trial Assessing the Efficacy of Carboxy-gel in Reducing Bruising and P · Phase 4 · recruiting
Other Beijing InnoCare Pharma Tech Co., Ltd. trials
Trials by the same sponsor.
- NCT06775860 — ICP-332 in Subjects With Moderate to Severe Atopic Dermatitis · Phase 3 · recruiting
- NCT06378138 — ICP-248 in Combination With Orelabrutinib in Treatment-naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (AP · Phase 2, PHASE3 · recruiting
- NCT06109818 — Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of ICP-488 in Patients with Moderate to Severe Plaque Psoriasis · Phase 2 · completed
- NCT06082102 — Efficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients Wit · Phase 3 · recruiting
- NCT06004856 — Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Chronic Primary Immune Thrombocytopenia · Phase 3 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05210868 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Beijing InnoCare Pharma Tech Co., Ltd.
- Last refreshed: 27 January 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05210868.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing